Mardepodect (PF-2545920)
99%
- Product Code: 58689
CAS:
1292799-56-4
| Molecular Weight: | 392.45 g./mol | Molecular Formula: | C₂₅H₂₀N₄O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Mardepodect (PF-2545920) is primarily investigated for its potential therapeutic applications in the field of neuroscience, particularly in the treatment of psychiatric disorders. It acts as a potent and selective phosphodiesterase 10A (PDE10A) inhibitor, which plays a crucial role in regulating intracellular signaling pathways in the brain. By inhibiting PDE10A, it enhances the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), leading to improved neurotransmission and neuronal function. This mechanism makes it a promising candidate for addressing conditions such as schizophrenia, where dopamine and glutamate signaling are dysregulated. Preclinical studies have shown its efficacy in improving cognitive and behavioral symptoms associated with the disorder. Additionally, its potential in treating other neuropsychiatric conditions, such as Huntington's disease and Parkinson's disease, is being explored due to its neuroprotective and modulatory effects on striatal pathways.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | €105.00 |
+
-
|
| 0.005 | 10-20 days | €363.81 |
+
-
|
| 0.025 | 10-20 days | €1,061.88 |
+
-
|
Mardepodect (PF-2545920)
Mardepodect (PF-2545920) is primarily investigated for its potential therapeutic applications in the field of neuroscience, particularly in the treatment of psychiatric disorders. It acts as a potent and selective phosphodiesterase 10A (PDE10A) inhibitor, which plays a crucial role in regulating intracellular signaling pathways in the brain. By inhibiting PDE10A, it enhances the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), leading to improved neurotransmission and neuronal function. This mechanism makes it a promising candidate for addressing conditions such as schizophrenia, where dopamine and glutamate signaling are dysregulated. Preclinical studies have shown its efficacy in improving cognitive and behavioral symptoms associated with the disorder. Additionally, its potential in treating other neuropsychiatric conditions, such as Huntington's disease and Parkinson's disease, is being explored due to its neuroprotective and modulatory effects on striatal pathways.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :